Warm Autoimmune Hemolytic Anemia research hub
5 indexed studies · 2 currently recruiting
- active not recruitingPHASE3
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
This study investigates a new medicine, obexelimab, for Warm Autoimmune Hemolytic Anemia (wAIHA). It aims to see how well it works and if it's safe for people who haven't responded to previous treatments.
Italy · Poland · Spain - recruitingTherapeutic confirmatory (Phase III)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A SAFETY AND DOSE CONFIRMATION RUN-IN PERIOD, TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (SAPHIARE)
This study is testing a new medicine called Obexelimab for people with Warm Autoimmune Hemolytic Anemia (wAIHA). It wants to see if the medicine is safe and helps improve their red blood cell levels compared to a dummy treatment.
Spain · Italy · Poland - active not recruitingPHASE2, PHASE3
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
This study is looking into a new medication, M281, for adults with a blood condition called warm autoimmune hemolytic anemia (wAIHA). It aims to see if the medicine is effective and safe compared to a dummy treatment. Participants will be treated for a long time, with close monitoring.
United States · Brazil · China - active not recruitingPHASE1, PHASE2
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
This study looks at a new medicine called povetacicept for adults with rare blood conditions like Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (wAIHA), and Cold Agglutinin Disease (CAD). Researchers want to see if it's safe and helps improve these conditions.
United States · Australia · Austria - recruitingPHASE2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
This study looks at giving a second course of ianalumab to adults with certain blood conditions (ITP or wAIHA) if their first treatment worked but then stopped or wasn't enough. It's to see if a second round is safe and helps them again.
Argentina · Belgium · China